February 14 & 21, 2025
9:00 AM – 1:00 PM CST each day
Cost for the 2 days of programming: $300
For NPs and PAs
(MDs, PhDs, PsyDs, Students, Fellows,
Social Workers are welcome)
Virtual CE Learning Opportunity
Earn up to 8 CE Credits*
Includes 1 hour of CE in pharmacology
Description:
Learn about the biopsychosocial model of disorders of gut-brain interaction (DGBI) and how APPs can effectively address the psychosocial needs of patients with IBS-C and other DGBI to improve outcomes and quality of life.
Advanced Practice Providers (APPs; NPs/PAs) are taking an increasingly important role in the management of patients with DGBI. This 8-hour introductory workshop will provide practical guidance for APPs on how to identify and address psychosocial and behavioral factors contributing to brain-gut dysregulation in patients with IBS-C. The course will provide education on the biopsychosocial model of IBS-C as well as behavioral tools to enhance clinical practice, including motivational interviewing techniques, diaphragmatic breathing skills, how to refer for behavioral treatment, and the use of central neuromodulators to treat DGBI. This course is targeted for APPs, although any healthcare professional involved in caring for patients with DGBI is welcome to attend.
Schedule:
Friday, February 14th
TIME (CST): TOPIC SPEAKERS
9:00 – 9:05 AM: Welcome and Introduction
9:05 – 9:50 AM: IBS-C: Definition, Burden, and Biopsychosocial Model: Laurie Keefer, PhD
9:50 – 10:20 AM: Assessing GI-Specific Psychosocial Factors in Patients with DGBI: Sarah Ballou, PhD
10:20 – 10:50 AM: Trauma-Informed Care: Alyse Bedell, PhD, CST
10:50 – 11:05 AM: Break
11:05 – 11:50 AM: GI- Focused Cognitive Behavioral Therapy: Helen Burton Murray, PhD
11:50 AM – 12:35 PM: Motivational Interviewing and Brief Action Planning: Brian Arizmendi, PhD, ABPP
12:35 – 12:55 PM: Q&A Panel Speakers
12:55 – 1:00 PM: Wrap-up and Closing
Friday, February 21st
TIME (CST): TOPIC SPEAKERS
9:00 – 9:05 AM: Welcome and Introduction
9:05 – 9:30 AM: Gut-Directed Hypnosis: Sarah Kinsinger, PhD, ABPP
9:30 – 9:50 AM: Diaphragmatic Breathing: Kate Tomasino, PhD
9:50 – 10:30 AM: Lifestyle Interventions for IBS-C: Kendra Kamp, PhD
10:30 – 10:40 AM: Break
10:40 – 11:00 AM: Psychoeducation and Referral Strategies: Lin Chang, MD
11:00 – 11:15 AM: Integrating Digital Therapeutics and Self-Guided Resources: Sarah Kinsinger, PhD, ABPP
11:15 AM – 12:10 PM: Central Neuromodulators for DGBI care and IBS-C management: Greg Sayuk, MD
12:10 – 12:15 PM: Break
12:15 – 12:55 PM: Skills Integration and Models of Care Provider Panel: Jean Fox, MD, Xiao Jing (Iris) Wang, MD, Samantha Calabrese, AGNP-BC, Amy Ladewski, PA-C, MMS, RD
12:55 – 1:00 PM: Wrap-up and Closing
Learning Objectives:
- Discuss the pathophysiology of disorders of gut-brain interaction, including the role of psychological processes.
- Explain how to assess for GI-specific psychological processes in patients with IBS-C in your clinical encounters.
- Explain three ways to utilize a trauma-informed approach in the care of patients with DGBI.
- List three evidence-based lifestyle behaviors for patients with IBS-CDemonstrate the use of active listening and open-ended questions as motivational interviewing techniques.
- Explain the Cognitive-Behavioral Therapy model as it applies to IBS-C
- Describe the rationale for utilizing gut-directed hypnotherapy to treat IBS-C
- Explain the brain-gut connection and rationale for behavioral treatment in patient-friendly terms
- Discuss the benefits and limitations of digital therapeutics for IBS
- Provide two examples of how behavioral treatments can be integrated into the clinical practice settings for APPs
Speakers:
Sponsored by
* Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Rome Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live for a maximum of 8 AMA PRA Category 8 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Psychologist Education
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
Credit Designation
This program offers 8 continuing education credits for physicians and psychologists. Includes 1 hour of CE in pharmacology.
Disclosure of Conflicts of Interest
Laurie Keefer, PhD
Consultant/Advisory Board: Coprata Health, AbbVie, Pfizer, Takeda, Ardelyx, Eli Lilly, Trellus Health
Non-Mutual funds Stock Ownership/Stock options: Trellus Health
Patent Holder/Royalties paid to you: metaMe Health
Sarah Kinsinger, PhD
Speakers Bureau/Honoraria for non-CME: Ardelyx
Consultant/Advisory Board: Ardelyx, metaMe Health, Mahana Therapeutics, Allay Health
Patent Holder/Royalties paid to you: metaMe Health
Sara Ballou, PhD
Private Practice
Psychotherapy
Alyse Bedell, PhD, CST
None
Helen Burton-Murray
Other financial or material support: Oxford University Press
Brian Arizmendi, PhD ABPP
None
Kathryn Tomasino, PhD
None
Kendra Kamp
None
Lin Chang, MD
Grant/Research Support: AnX Robotica, Arena, Ironwood, Vanda Speakers Bureau/Honoraria for non-CME: Abbvie, Ironwood
Consultant/Advisory Board: Ardelyx, Arena, Atmo, Bausche Health, Ironwood, Trellus Health, Food Marble, Vibrant
Non-Mutual funds Stock Ownership/Stock options: Modify Health, Trellus Health, Food Marble
Patent Holder/ Royalties paid to you: DNA methylation based biomarkers for irritable bowel syndrome, Ref.: 2018-578-2, UCLA reference UCLA.260WOU1, filed 5/31/2019. 2. DNA methylation-based algorithm to diagnose irritable bowel syndrome and other GI conditions. U.S. Provisional Patent Application Serial No.: 63/499,017, filed on 4/28/2023.
Gregory Sayuk
Speakers Bureau/Honoraria for non-CME: Salix, AbbVie, Ironwood, Ardelyx, Sanofi, Renegeron
Consultant/Advisory Board: Salix, AbbVie, Ironwood, Ardelyx, Sanofi, Regeneron
Jean Fox, MD
Employee: Mayo Clinic
Grant/Research Support: Mayo Clinic
Xiao Jing Wang
None
Samatha Calabrese
Speakers Bureau/Honoraria for non-CME: Focus Medical Communications
Amy Ladewski, PA-C, MMS, RD
None